Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON
  1. Accueil Zonebourse
  2. Actions
  3. Australie
  4. Australian Stock Exchange
  5. Immutep Limited
  6. Actualités
  7. Autres langues
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur IMMUTEP LIMITED
2021Immutep Taps Northway Biotech To Manufature Autoimmune Drug IMP761
2021IMMUTEP : Advances IMP761 Manufacturing - Form 6-K
2021Immutep Limited Advances IMP761 Manufacturing
2021Immutep Signs Deal for Clinical Trial Production of Autoimmune Drug
2021IMMUTEP : Advances IMP761 Manufacturing
2021IMMUTEP : Amended Constitution
2021Immutep Limited Announces Change of Registered Office Address, Effective 15 December 20..
2021IMMUTEP : Change in substantial holding
2021IMMUTEP : REPORTS GOOD SAFETY FROM FIRST FIVE PATIENTS IN TRIPLE COMBINATION THERAPY EFTI ..
2021Immutep Doses First Five Patients in Study of Triple Combination Cancer Treatment, Find..
2021IMMUTEP : Reports Good Safety from First Five Patients in Triple Combination Therapy Efti ..
2021Immutep Limited Reports Good Safety from First Five Patients in the INSIGHT-003 study
2021IMMUTEP : Application for quotation of securities - IMM
2021IMMUTEP : Notification regarding unquoted securities - IMM
2021IMMUTEP : Results of Annual General Meeting
2021IMMUTEP : AGM 2021 - Chairman's Address
2021IMMUTEP : AGM 2021 - CEO's presentation
2021IMMUTEP : Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy..
2021IMMUTEP : Goetzpartners securities -Data highlights efti efficacy and potential central ro..
2021Immutep Completes Recruitment for Phase 2 Study of Therapy Candidate for Several Types ..
2021Immutep Completes Recruitment for Phase 2 Cancer Trial
2021IMMUTEP : Phase II TACTI-002-002 trial recruitment successfully completed
2021Immutep Limited Announces the Enrollment of Last Patient in the Expansion Stage of Part..
2021IMMUTEP : Maxim Group - AIPAC Presentation at SITC Builds on Prior Data, Prepping to Go Pi..
2021IMMUTEP : Wilsons Equity Research - Immutep Limited (IMM) | Efti impresses in HNSCC and ai..
2021IMMUTEP : Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New..
2021Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, i..
2021Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive Ne..
2021Immutep Secures Chinese Patent for Immunotherapy Drug Candidate
2021IMMUTEP : Chinese patent Granted for Efti with PD-1 Pathway Inhibitors
2021IMMUTEP : announces publication of SITC 2021 posters
2021Immutep Limited Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters At SITC with Pos..
2021Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive Ne..
2021SITC 2021 - TACTI-002 Poster
2021SITC 2021 - TACTI-003 Poster
2021SITC 2021 - AIPAC Poster
2021Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021..
2021AIPAC FINAL DATA AS EXPECTED : Phase III supported with maintaining a Buy Rating (ASX:IMM)..
2021Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021..
2021Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembroli..
2021Late Breaking Abstract for SITC 2021 - AIPAC
2021TACTI-003 : A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizuma..
2021Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key P..
2021Immutep Limited Reports Improved and Statistically Significant Survival Benefit for Thr..
2021O/W : IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Me..
2021IMMUTEP GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBI..
2021Immutep Secures Chinese Patent for Anti-Cancer Lead Product Candidate
2021Immutep granted chinese patent for eftilagimod alpha, a soluble lag-3 protein, in combi..
2021Immutep Receives Positive Feedback From European Medicines Agency About Efti to Treat B..
2021Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Eft..
2021Immutep Limited Receives Positive EMA Scientific Advice for Further Clinical Developmen..
2021Immutep receives positive EMA scientific advice for further clinical development of eft..
2021Immutep Receives Scientific Advice for Clinical Development of Cancer Drug
2021Immutep receives EMA scientific advice in Phase 3 in MBC
2021Immutep Limited Receives EMA Scientific Advice for Phase 3 in MBC
2021Immutep Quarterly Activities Report & Appendix 4C - Form 6-K
2021Immutep Limited Provides an Update on the Ongoing Development of its Product Candidate
2021Immutep Quarterly Activities Report & Appendix 4C
2021IMMUTEP : Corporate Connect - A Truly Undervalued Company
2021IMMUTEP : 2021 Annual General Meeting and Key Dates
2021IMMUTEP : to Present Data, Trial Design of Clinical Studies for Cancer Treatments During M..
2021IMMUTEP : to present Phase II TACTI-002 data at SITC 2021
2021IMMUTEP : to Present Phase II TACTI-002 Data at SITC 2021
2021IMMUTEP : Receives $2.49 Million as R&D Tax Incentive from French Government
2021IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government
2021IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government (Form 6-K)
2021IMMUTEP : Receives $2.5 Million Tax Incentive from France
2021IMMUTEP : Receives A$3.4 million R&D French Tax Incentive
2021IMMUTEP : to Present at Healthcare Investor Conferences
2021Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking ..
2021Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking ..
2021IMMUTEP : Maxim Group - The Case for LAG-3 is Building
2021IMMUTEP : ESMO 2021 – INSIGHT - Stratum D Poster
2021IMMUTEP LIMITED(NASDAQGM : IMMP) added to S&P Global BMI Index
2021IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-..
1  2  3  4  5  6  7  8Suiv.